Kirom Bukhoroi

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc. (KRBP) and Encourages Investors with Significant Losses to Contact the Firm

Retrieved on: 
Friday, August 19, 2022 - 2:15pm
Class Action Lawsuit, Professional Services, Legal, Investigational New Drug, Artificial intelligence, IND, Insurance, NASDAQ, LLP, Time, IPO, AND, Lead, Immunotherapy, FDA, Fraud, COPY, CLASS, COMMON, Private investigator, Pharmaceutical industry, Kirom Bukhoroi

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. (Kiromic) ( NASDAQ: KRBP ).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. (Kiromic) ( NASDAQ: KRBP ).
  • As a result of Kiromics materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Kiromic investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Kiromic BioPharma, Inc.

Retrieved on: 
Thursday, August 18, 2022 - 10:27pm
FDA, GLOBE, COMMON, IND, CLASS, LLP, AND, Fraud, District court, NASDAQ, Artificial intelligence, Lead, Immunotherapy, COPY, Insurance, Time, IPO, Investigational New Drug, Private investigator, Pharmaceutical industry, Architecture, Kirom Bukhoroi

Kessler Topaz Meltzer & Check, LLP encourages Kiromic investors who have suffered significant losses to contact the firm directly to acquire more information.

Key Points: 
  • Kessler Topaz Meltzer & Check, LLP encourages Kiromic investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .

KRBP ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in Kiromic BioPharma (KRBP) with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Retrieved on: 
Tuesday, August 16, 2022 - 9:48pm
FDA, Steve Berman (lawyer), GLOBE, SEC, Cancer, IND, Company, Person, SAN, Program, Fraud, NASDAQ, KRBP, News, Investigational New Drug, Pharmaceutical industry, Kirom Bukhoroi

SAN FRANCISCO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Retrieved on: 
Tuesday, August 16, 2022 - 7:53pm
Titan, FDA, Investigational New Drug, GLOBE, TO, Food and Drug Administration Amendments Act of 2007, Facebook, IND, Advertising, Kirom Bukhoroi, Court, Company, Twitter, I-Space (Chinese company), WHY, NASDAQ, Immunotherapy, LinkedIn, THE, IPO, Food, Insurance, Tobacco, Pharmaceutical industry

WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, and Kiromic and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 16, 2022 - 2:00am
FDA, P.C, Bankruptcy, Disclosure, Documentation, Risk, NYSE, Â, GLOBE, Georgetown University Law Center, Technology, Ecosystem, Coinbase, SEC, Bloomberg, IND, Chemistry (relationship), Texas Law Review, Kirom Bukhoroi, Prospectus, Lists of schools in England, Company, Credit risk, Complaint, Register, NASDAQ, Immunotherapy, News, Offering, IPO, Cryptocurrency, Security (finance), Renewable energy, Audit, Pharmaceutical industry, Carvana

Coinbase provides financial infrastructure and technology products and services for the cryptocurrency economy (or cryptoeconomy) in the U.S. and internationally.

Key Points: 
  • Coinbase provides financial infrastructure and technology products and services for the cryptocurrency economy (or cryptoeconomy) in the U.S. and internationally.
  • Following this disclosure, the price of Coinbases Class A common stock fell $19.27 per share, or 26.4%, to close at $53.72 per share on May 11, 2022.
  • For more information on the Kiromic class action go to: https://bespc.com/cases/KRBP
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Kiromic Biopharma, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)

Retrieved on: 
Friday, August 12, 2022 - 5:05pm
Class Action Lawsuit, Professional Services, Legal, Steps, FDA, Drug Quality and Security Act, Intelligence, Securities Exchange Act of 1934, Kirom Bukhoroi, Patient, Company, NASDAQ, Inc., KRBP, Immunotherapy, Securities Act of 1933, IPO, Complaint, Person, Medical device

Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.

Key Points: 
  • Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.
  • If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
  • Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Carvana and Kiromic and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, August 11, 2022 - 2:00am
FDA, P.C, Documentation, Risk, NYSE, GLOBE, IND, Chemistry (relationship), Kirom Bukhoroi, Prospectus, Lists of schools in England, Company, Complaint, Register, NASDAQ, Immunotherapy, News, Offering, IPO, Pharmaceutical industry, Audit, Carvana

On June 24, 2022, Barrons published an article entitled Carvana Sought to Disrupt Auto Sales.

Key Points: 
  • On June 24, 2022, Barrons published an article entitled Carvana Sought to Disrupt Auto Sales.
  • On this news, Carvanas share price fell approximately 21% over the next two trading days, damaging investors.
  • For more information on the Kiromic class action go to: https://bespc.com/cases/KRBP
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

EQUITY ALERT: Rosen Law Firm Encourages Kiromic BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Retrieved on: 
Wednesday, August 10, 2022 - 10:51pm
Class Action Lawsuit, Professional Services, Legal, Titan, FDA, Investigational New Drug, TO, Food and Drug Administration Amendments Act of 2007, Facebook, IND, Advertising, Kirom Bukhoroi, Court, Company, Twitter, I-Space (Chinese company), WHY, NASDAQ, Immunotherapy, LinkedIn, THE, IPO, Food, Insurance, Tobacco, Pharmaceutical industry

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.

Key Points: 
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)

Retrieved on: 
Wednesday, August 10, 2022 - 3:49am
Class Action Lawsuit, Professional Services, Legal, Steps, FDA, Securities Act of 1933, Intelligence, Securities Exchange Act of 1934, SEC, Prospectus, Kirom Bukhoroi, Patient, Company, NASDAQ, Inc., Immunotherapy, KRBP, IPO, Complaint, Person, Medical device

Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.

Key Points: 
  • Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.
  • If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
  • Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

KIROMIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, August 10, 2022 - 2:00am
Class Action Lawsuit, Professional Services, Legal, FDA, P.C, Telephone, IND, Kirom Bukhoroi, Prospectus, Court, Company, Complaint, Register, NASDAQ, Immunotherapy, Jeanne Eagels, Offering, IPO, Person, Pharmaceutical industry

Investors have until October 4, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until October 4, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021.
  • Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDAs imposition of a clinical hold.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.